Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:40
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:39
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:39
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:39
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:38
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:38
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:38
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:37
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:37
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:36
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:35
Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re Headed
Submitted by web@researchtop... on Thu, 10/24/2013 - 13:14
RCCUTT113
Submitted by Anonymous on Wed, 10/23/2013 - 12:33
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of renal cell cancer.
Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?
Submitted by Anonymous on Fri, 10/18/2013 - 17:12
Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?
Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive?
Did that patient receive regorafenib at some point during his or her course of metastatic disease?
Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?
Submitted by Anonymous on Fri, 10/18/2013 - 16:50
Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?
Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive?
Did that patient receive regorafenib at some point during his or her course of metastatic disease?